Enanta Pharmaceuticals (ENTA) EBT Margin (2012 - 2026)
Enanta Pharmaceuticals posted quarterly EBT Margin of 76.25% for Q1 2026, up 8420.0% year-on-year from 0.89% in Q1 2025, and down 19.14% on a QoQ basis from 64.0% in Q4 2025.
Enanta Pharmaceuticals (ENTA) has 15 years of EBT Margin data on file, last reported at 76.25% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 8420.0% year-over-year to 76.25%; the trailing twelve-month figure through Mar 2026 stood at 89.42% (up 6399.0% YoY), and the FY2025 full-year result was 127.9%, up 4625.0% from the prior year.
- EBT Margin for Q1 2026 stood at 76.25%, down from 64.0% in the prior quarter.
- Across five years, EBT Margin topped out at 64.0% in Q4 2025 and bottomed at 211.37% in Q1 2023.
- The 5-year median for EBT Margin is 155.91% (2023), against an average of 147.55%.
- The widest annual swing landed in 2023, when EBT Margin slumped 6597 bps; it then jumped 8420 bps in 2026.
- A 5-year view of EBT Margin shows it stood at 123.04% in 2022, then tumbled by 54 bps to 189.02% in 2023, then climbed by 29 bps to 133.89% in 2024, then soared by 52 bps to 64.0% in 2025, then slipped by 19 bps to 76.25% in 2026.
- The last three EBT Margin figures came in at 76.25% (Q1 2026), 64.0% (Q4 2025), and 123.42% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - | -76.25% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -76.25% |
| Dec 31, 2025 | -64.00% |
| Sep 30, 2025 | -123.42% |
| Jun 30, 2025 | -99.52% |
| Mar 31, 2025 | -160.45% |
| Dec 31, 2024 | -133.89% |
| Sep 30, 2024 | -199.81% |
| Jun 30, 2024 | -128.28% |
| Mar 31, 2024 | -184.82% |
| Dec 31, 2023 | -189.02% |
| Sep 30, 2023 | -155.91% |
| Jun 30, 2023 | -184.44% |
| Mar 31, 2023 | -211.37% |
| Dec 31, 2022 | -123.04% |
| Sep 30, 2022 | -129.62% |
| Jun 30, 2022 | -165.03% |
| Mar 31, 2022 | -179.48% |
| Dec 31, 2021 | -109.05% |
| Sep 30, 2021 | -141.65% |
| Jun 30, 2021 | -154.50% |
| Mar 31, 2021 | -144.82% |
| Dec 31, 2020 | -36.61% |
| Sep 30, 2020 | -78.85% |
| Jun 30, 2020 | -114.76% |
| Mar 31, 2020 | -35.94% |
| Dec 31, 2019 | 28.43% |
| Sep 30, 2019 | 16.96% |
| Jun 30, 2019 | 13.91% |
| Mar 31, 2019 | 2.37% |
| Dec 31, 2018 | 42.56% |
| Sep 30, 2018 | 53.39% |
| Jun 30, 2018 | 41.87% |
| Mar 31, 2018 | 40.69% |
| Dec 31, 2017 | 40.25% |
| Sep 30, 2017 | 72.38% |
| Jun 30, 2017 | -166.81% |
| Mar 31, 2017 | -99.98% |
| Dec 31, 2016 | -62.61% |
| Sep 30, 2016 | -20.47% |
| Jun 30, 2016 | -4.59% |
| Mar 31, 2016 | -0.72% |
| Dec 31, 2015 | 74.15% |
| Sep 30, 2015 | 29.02% |
| Jun 30, 2015 | 17.16% |
| Mar 31, 2015 | 85.02% |
| Dec 31, 2014 | 90.98% |
| Sep 30, 2014 | -193.02% |
| Jun 30, 2014 | 83.07% |
| Mar 31, 2014 | -240.88% |
| Dec 31, 2013 | -601.34% |
| Sep 30, 2013 | -329.36% |
| Jun 30, 2013 | -250.94% |
| Mar 31, 2013 | -331.35% |
| Dec 31, 2012 | 78.74% |
| Sep 30, 2012 | -218.25% |
| Jun 30, 2012 | -136.90% |
| Mar 31, 2012 | 87.82% |